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ABSTRACT
In previous studies, we have demonstrated the inhibition of CD4 expression in rat lymphocytes
treated with phorbol myristate acetate (PMA) by antisense oligonucleotides (AS-ODNs) directed
against the AUG start region of the cd4 gene. The aim of the present study was to inhibit CD4 ex-
pression in lymphocytes without promoting CD4 synthesis and to determine the effect of this inhibi-
tion on CD41 T cell function. Four 21-mer ODNs against the rat cd4 gene (AS-CD4-1 to AS-CD4-4)
were used. Surface CD4 expression was measured by immunofluorescence staining and flow cytom-
etry, and mRNA CD4 expression was measured by RT-PCR. T CD41 cell function was determined
by specific and unspecific proliferative response of rat-primed lymphocytes. After 24 hours of incu-
bation, AS-CD4-2 and AS-CD4-4 reduced lymphocyte surface CD4 expression by 40%. This effect
remained for 72 hours and was not observed on other surface molecules, such as CD3, CD5, or CD8.
CD4 mRNA expression was reduced up to 40% at 24 hours with AS-CD4-2 and AS-CD4-4. After 48
hours treatment, CD4 mRNA decreased up to 27% and 29% for AS-CD4-2 and AS-CD4-4, respec-
tively. AS-CD4-2 and AS-CD4-4 inhibited T CD41 cell proliferative response upon antigen-specific
and unspecific stimuli. Therefore, AS-ODNs against CD4 molecules inhibited surface and mRNA
CD4 expression, under physiologic turnover and, consequently, modulate T CD41 cell reactivity.
INTRODUCTION
CD4 IS A 55–59 kDa nonpolymorphic membrane gly-coprotein expressed on T helper (Th) lymphocytes
that stabilizes the physical interactions between CD41 T
cells and antigen-presenting cells (APC) by binding to
the MHC II expressed on APCs (Janeway, 1989; Cam-
marota et al., 1992). Strategies binding CD4 avoid the in-
teraction between Th and APC and, therefore, inhibit the
immune response. In this regard, anti-CD4 monoclonal
antibodies (mAb) efficiently induce immune tolerance in
the treatment of human and experimental autoimmune
diseases (Mauri et al., 1997; Isaacs et al., 1999; reviewed
in Nepom, 2002) and in the prevention of transplantation
rejection (Mottram et al., 1998; Motoyama et al., 2000;
reviewed in Adler and Turka, 2002). Anti-CD4 mAb
therapy prevents and improves rat adjuvant arthritis
(Pelegrí et al., 1995, 1996) associated with a decrease in
Th1-like cells (Pelegrí et al., 2001). In addition, it has
proved efficient in other animal models of rheumatoid
arthritis (Van den Broek et al., 1992; Chu and Londei,
1996; Mauri et al., 1997) and in clinical studies (Van der
Lubbe et al., 1997; Schulze-Koops et al., 1998). In rheu-
matoid arthritis, preliminary results of open-label trials
with two humanized nondepleting anti-CD4 mAb sug-
gest a clinical benefit with a transient reduction in CD41
T cells (Keystone, 2002). However, these treatments may
induce an anti-mAb response that neutralizes the drug
and so disables the treatment after several doses (Pelegrí
et al., 1996).
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Gene therapy appears to hold promise for more specific
treatments. Gene therapy in autoimmune diseases may re-
place or compensate for defective or missing genes, de-
liver immunomodulating molecules, and interfere with
signaling processes involved in autoimmune reactions
(reviewed in Robbins et al., 2003). Immune responses are
initiated by the presentation of antigen T lymphocytes and
require the interaction between costimulatory molecules
on the APC and T lymphocyte. Interfering costimulation
not only inhibits the immune response but also induces
anergy in the epitopes presented in the absence of 
costimulation (reviewed in Robbins et al., 2003). Anti-
gen-specific anergy would have many advantages for
the treatment of autoimmune disorders. Antisense
oligonucleotides (AS-ODNs) may be a powerful tool to
selectively inhibit the expression of a target protein in-
volved in autoimmune disorders. 
In previous studies, we have demonstrated that AS-
ODNs reduce CD4 expression in rat lymphocytes in
which CD4 synthesis is stimulated by phorbol myristate
acetate (PMA) (Rabanal et al., 2002). The aim of the
present study was to inhibit CD4 expression in rat T lym-
phocytes by AS-ODNs without promoting CD4 synthesis
and to assess the effect of this inhibition on T CD41 cell
proliferative response.
MATERIALS AND METHODS
AS-ODNs
Four 21-mer oligonucleotides (AS-CD4-1 to 4) against
the initiation of translation of the cd4 rat mRNA (Clark et
al., 1987) were designed. The sequences of these AS-
ODNs are shown in Table 1. AS-CD4-1 was totally phos-
phothioate (PS) modified to increase its resistance to 
nuclease degradation. AS-CD4-2, AS-CD4-3, and AS-
CD4-4 were PS-modified at the 39-end and 59-end and
the internal pyrimidine residues (partially PS-modified)
(Peyman and Uhlmann, 1996). Three control ODNs were
designed: ODN-C1 was totally PS-modified, and its se-
quence corresponded to a scrambled AS-CD4-1; ODN-
C2, a partially PS-modified ODN, was a mismatch (four
bases) of AS-CD4-2; ODN-C4, a partially PS-modified
ODN, was a mismatch (four bases) of AS-CD4-4. All
these ODNs were synthesized by TIB Molbiol Synthese-
labor (Berlin, Germany).
Animals
Female Wistar rats (Charles River, Barcelona, Spain)
weighing 180–200 g were used as the lymphocyte
source. The study was in compliance with the guidelines
for the care and use of laboratory animals approved by
the Ethics Commission for Animal Experimentation of
the University of Barcelona.
Lymphocyte isolation and culture
Samples were obtained early in the morning (resting
phase of rats) when the circadian rhythm of CD4 surface
expression was minimal, and the amount of blood Th
lymphocytes was almost maximal (Pelegrí et al., 2003).
To study CD4 mRNA expression, peripheral blood lym-
phocytes (PBL) isolated by Nycoprep® gradient centrifu-
gation (Nycomed, Oslo, Norway) were used. To study
CD4 surface expression, spleen lymphocytes were iso-
lated as described elsewhere (Rabanal et al., 2002). Cells
(2 3 105/200 ml) were cultured in RPMI 1640 medium
supplemented with 1% fetal bovine serum (FBS), 50 mM
2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine, 1% nonessential amino
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TABLE 1. SEQUENCES OF ANTISENSE OLIGONUCLEOTIDES AND CONTROL OLIGONUCLEOTIDES
USED IN THIS STUDY, INCLUDING POSITION OF TARGET SITES
Name Sequence (59 ® 39) Target sequence
AS-CD4-1 G*A*A*A*G*A*G*A*A*G*C*C*T*C*G*G*C*A*C*A*T* AUG start codon
(11 ® 121)
AS-CD4-2 G*A*A*A G A G A A G C*C*T*C*G G C*A*C*A*T* AUG start codon
(11 ® 121)
AS-CD4-3 C*A*T*G G T*G G C*C*T*G C*T*T*G A G C*G*G* AUG start codon
(218 ® 13)
AS-CD4-4 C*G*G*C*A C*A T*G G T*G G C*C*T*G C*T*T*G* AUG start codon
(213 ® 18)
ODN-C1 A*G*G*C*T*A*A*C*G*A*T*C*C*A*C*A*G*A*G*G*A* None
ODN-C2 G*A*A*AGAGAAGC*C*T*GC*C*GA*C*A*T* None
ODN-C4 C*G*G**AC*AT*GGT*C*C*GGT*GC*T*T*G* None
*PS modifications.
acids, and 1% sodium pyruvate (Bio-Whittaker Europe,
Verviers, Belgium) (RPMI complete medium) for 1–3
days.
ODN treatment
ODNs were mixed with the cationic liposome DOTAP
(Roche Diagnostics, Barcelona, Spain) for 20 minutes at
ambient temperature and then added to lymphocyte cul-
tures in 20 ml TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8). As controls, lymphocytes were treated either with
DOTAP alone or with the same volume of TE buffer (un-
treated cells).
Immunofluorescence staining and flow cytometry
To quantify CD4 surface expression, FITC-conjugated
W3/25 mAb (mouse IgG1, antirat CD4 mAb) was used.
To determine cell surface CD8, CD5, and CD3 expres-
sion, the following mAbs were used: FITC-conjugated
OX8 mAb (mouse IgG1, antirat CD8) (Labgen,
Barcelona, Spain), FITC-conjugated OX19 mAb (mouse
IgG1, antirat CD5) (Labgen), and 1F4 mAb (mouse IgG1
antirat CD3) (PharMingen, Hamburg, Germany), respec-
tively. Goat antimouse FITC immunoglobulin (Sigma,
Barcelona, Spain) was used as secondary antibody in the
last mAb.
Antibodies were added to the cells at previously es-
tablished saturating concentrations and incubated for
30 minutes at 4°C with phosphate-buffered saline
(PBS) with 0.1% sodium azide and 2% FBS. After
washing, lymphocytes were fixed in 0.5% p-formalde-
hyde in NaCl solution (0.9%) and stored at 4°C in the
dark until analyses were performed. Viable cells with
the forward and side-scatter characteristics of lym-
phocytes were analyzed on an Epics XL Flow Cy-
tometer (Coulter Corp., Hialeah, FL). Cytometer soft-
ware (System II Software v. 3.0, Coulter Corp.)
allowed calculation of the mean fluorescence intensity
(MFI), which was proportional to the amount of spe-
cific target on cell surface (Arosa and de Sousa, 1995;
Jason and Inge, 2001). Results are expressed as the
percentage of inhibition according to the following
formula:
MFI of untreated lymphocytes 2
MFI of ODN lymphocytes 3 100
MFI of untreated lymphocytes
Toxicity studies
Cell viability in the presence of ODNs and DOTAP
was determined by flow cytometry using propidium io-
dide (PI) and fluorescein diacetate (FDA) (Sigma). Liv-
ing cells were positive for FDA and negative for PI
(Darzynkiewicz et al., 1994).
Quantitative RT-PCR
Total RNA was extracted both from ODN-treated and
untreated PBLs using the Ultraspec™ RNA reagent
(Biotecx, Barcelona, Spain) in accordance with the man-
ufacturer’s instructions. cDNA was synthesized in a 20-
ml reaction mixture containing 1 mg RNA, 125 ng ran-
dom hexamers (Boehringer Mannheim, Barcelona,
Spain), 10 mM dithiothreitol, 20 U RNAsin (Promega,
Barcelona, Spain), 0.5 mM dNTPs (Applichem, Madrid,
Spain), 4 ml of 53 RT buffer, and 200 U MLV RT (last
two from BRL, Barcelona, Spain). The reaction mixture
was incubated at 37°C for 60 minutes, and 5 ml of the
cDNA mixture was used for PCR amplification.
PCR reactions were carried out as follows. A standard
50-ml mixture contained 5 ml of the cDNA mixture, 4 ml of
103 PCR buffer (Mg21 free), 1.5 mM MgCl2, 0.2 mM
dNTPs, 2.5 mCi of a32P-dATP (3000 Ci/mmol) (Amer-
sham, Madrid, Spain), 2.5 U Taq polymerase (GIBCO,
Barcelona, Spain), and 500 ng of each primer. The CD4
primers used were 59-TCCCAGCGTCGTGATTAGTG-39
and 59-CACTGTGTGGGCTACATTC-39 and, for hypo-
xanthine phosphoribosyl transferase (HPRT) mRNA,
which was used as control, 59-TCCCAGCGTCGTGA-
TTAGTG-39 and 59-GGCTTTTCCACTTTCGCTGA-39.
The reaction mixture was separated in two phases by a
solid parafilm wax layer (melting T 5 58–60°C) (Fluka,
Madrid, Spain), preventing the complete mixing of PCR
reactants until the reaction reached a temperature that
minimizes the nonspecific annealing of primers to non-
target DNA. The lower solution contained the MgCl2, the
dNTPs, the primers, the a32P-dATP, and half of the
buffer, and the upper solution contained the cDNA, the
Taq enzyme, and the remaining buffer. PCR was per-
formed for 28 cycles for CD4 and 23 cycles for HPRT,
after 1 minute denaturation at 94°C. Each cycle consisted
of denaturation at 92°C for 30 seconds, primer annealing
at 57°C for CD4 or 60°C for HPRT for 1 minute, and
primer extension at 72°C for 1 minute. Each PCR sample
(5 ml) was electrophoresed in a 5% polyacrylamide gel.
The gel was dried, and the radioactive bands were quan-
titated by phosphorimaging (Molecular Dynamics,
Madrid, Spain). The sizes of the amplified products were
1073 bp for CD4 and 608 bp for HPRT.
ODN on proliferative response of primed 
T CD41 lymphocytes
A group of animals were i.p. immunized with 0.1
mg/kg ovalbumin (OA, grade V) (Sigma) in Inject®
Alum (Pierce, Rockford, IL). After 4 weeks, OA immu-
nization was confirmed by specific antibody levels by
ELISA (Salgado et al., 1988). Spleen lymphocytes were
isolated as described. T cells were purified by passage
through nylon wool, and T CD41 cells were negatively
isolated with FITC-conjugated antirat CD8 mAb and
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then passed through a MoFlo® Cell Sorter (DakoCytoma-
tion, Carpinteria, CA). T CD41 cells were $95%, as as-
sessed by flow cytometry. Dendritic cells (DC) were ob-
tained from unprimed rat spleen by Optiprep® gradient
(Nycomed).
T CD41 cells (1 3 105/well) were treated with ODN-
C1, ODN-C4, AS-CD4-2, or AS-CD4-4 at optimal
doses. After 24 hours, 1 3 104 DC treated with mito-
mycin C (50 mg/5 3 107 DC) (Sigma) per well were
added. T CD41 lymphocytes were subsequently stimu-
lated with OA (1 mg/ml) or casein, as control protein, for
96 hours. In a parallel experiment, T CD41 cells were
stimulated with concanavalin A (ConA) (Sigma) at 1
mg/ml for 48 hours. After incubation (37°C, 5% CO2),
the T CD41 cell proliferation was determined by a Cell
Proliferation Biotrak ELISA system (Amersham) based
on the measurement of 59-bromo-29-deoxyuridine
(BrdU) incorporation into newly synthesized DNA
(Porstmann et al., 1985). After reaction with peroxidase-
conjugated anti-BrdU antibody and a specific substrate,
absorbance was directly proportional to the amount of
DNA synthesized.
Statistical analysis
Results were statistically analysed by the nonparamet-
ric U Mann-Whitney test. All analyses were performed
using the Statistica computer package for Windows (Stat
Soft, Tulsa, OK). Significance was set at p , 0.05.
RESULTS
Lymphocyte viability with AS-ODNs and DOTAP
In previous studies, we have demonstrated by flow cy-
tometry and confocal microscopy that DOTAP was es-
sential to deliver AS-ODNs into rat lymphocytes (Ra-
banal et al., 2002). To determine the toxicity of DOTAP,
lymphocytes were incubated with the cationic liposome
at concentrations ranging between 5 and 20 mM and
analysed after 4 and 24 hours (Fig. 1A). DOTAP at all
the concentrations tested slightly reduced lymphocyte vi-
ability after 24 hours incubation. When ODN (0.1–5
mM) was added together with 10 mM DOTAP, no differ-
ences were observed between the concentrations assayed
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FIG. 1. (A) Effect of DOTAP concentrations (0–20 mM) on spleen lymphocyte viability. (B) Effect of several ODN-C1 concen-
trations (0.1–5 mM) with 10 mM DOTAP on spleen lymphocyte viability. Results are expressed as the percentage of living cells
(FDA1IP2). Each point represents the mean of six values 6 SEM.
(Fig. 1B). In any case, cell viability remained .70% af-
ter 24 hours.
Effect of AS-ODNs on CD4 surface expression
after 24 hours of incubation
CD4 expression was first studied in lymphocytes
treated with the totally PS-modified AS-CD4-1 (0.25–4
mM) mixed with DOTAP. AS-CD4-1 did not affect 
expression compared with that determined in lympho-
cytes treated with unspecific ODN-C1 (data not shown).
Thereafter, lymphocytes were incubated with the par-
tially PS-modified AS-CD4-2, -3, and -4 mixed with
DOTAP. Figure 2A shows the cytometry patterns corre-
sponding to unlabeled lymphocytes (black peak) and
lymphocytes treated either with DOTAP, DOTAP plus
AS-CD4-2, or untreated, after labeling with anti-CD4-
FITC mAb. Untreated labeled lymphocytes presented the
highest MFI as the positive peak was placed on the right.
Treatment with AS-CD4-2 displaced the positive peak
toward the negative one, which reflected a decrease in
MFI.
Results from lymphocytes incubated with increasing
concentrations of the partially PS-modified AS-CD4-2,
-3, and -4 (0.25–4 mM) mixed with a single concentration
of DOTAP (7.5 mM) are summarized in Figure 2B. AS-
CD4-2 and AS-CD4-4 inhibited CD4 surface expression
by almost 40%. The effect was not dose dependent be-
cause the maximal effect was detected at 0.5 and 0.75
mM for both AS-CD4-2 and AS-CD4-4. These effects
were significant compared with lymphocytes treated with
DOTAP alone and lymphocytes treated with ODN-C2
and ODN-C4 (p , 0.05). AS-CD4-3 showed a signifi-
cant effect only at 4 mM.
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FIG. 2. Effect of AS-ODNs on cell surface CD4 expression. (A) Cytometry patterns of unlabeled lymphocytes (black peak) and
lymphocytes treated with DOTAP, DOTAP plus AS-CD4-2, or untreated, after labeling with anti-CD4 mAb. (B) Effect of several
concentrations of the partially PS-modified ODNs (0.25–4 mM) with DOTAP (7.5 mM). Results are expressed as the percentage of
surface CD4 inhibition compared with that of untreated lymphocytes. (C) Effect of partially PS-modified ODNs (0.75 mM) mixed
with several concentrations of DOTAP (1.25–15 mM). Results are expressed as percentage of surface CD4 inhibition compared
with that of untreated lymphocytes. (D) Effect of increasing concentrations of two partially PS-modified ODNs together or sepa-
rately. Results are expressed as the percentage of surface CD4 inhibition compared with untreated lymphocytes. Each point repre-
sents the mean of five values 6 SEM.
The ODN/DOTAP ratio was subsequently analyzed
using AS-CD4-2, -3, and -4 at 0.75 mM with several con-
centrations of DOTAP (1.25–15 mM). Lymphocytes
treated with AS-CD4-2 showed the maximal inhibition
of CD4 expression at 7.5 mM DOTAP (ODN/DOTAP ra-
tio 1:10) (Fig. 2C). AS-CD4-4 exerted the same effect at
any ratio studied. This inhibitory effect was significant
compared with lymphocytes treated with DOTAP alone
and lymphocytes treated with ODN-C2 and ODN-C4
(p , 0.05). Maximal CD4 inhibition in lymphocytes
treated with AS-CD4-3 did not exceed 25% and was
achieved at 15 mM DOTAP. In this condition, the AS-
CD4-3 effect was significant compared with the lympho-
cytes treated with DOTAP and DOTAP plus ODN-C2
and ODN-C4 (p , 0.05).
The effectiveness of AS-CD4-2 and AS-CD4-4 was
also tested by adding increasing concentrations of AS-
ODNs mixed with DOTAP, keeping the ODN/DOTAP
ratio at 1:10 for AS-CD4-2 and 1:15 for AS-CD4-4. The
inhibitory effect of AS-CD4-4 remained around 30%
and, again, did not show dose dependence (Fig. 2D). On
the other hand, the dose-dependent response was quanti-
fied when AS-CD4-2 was added, reaching the maximal
effect at 0.75 mM ODN plus 7.5 mM DOTAP. The effec-
tiveness of AS-CD4-2 and AS-CD4-4 was also tested by
adding both AS-ODNs together at concentrations rang-
ing between 0.125 mM of AS-CD4-2 plus 0.083 mM AS-
CD4-4 and 0.75 mM AS-CD4-2 plus 0.5 mM AS-CD4-4.
Although a positive dose-response was found, no further
inhibition was detected at any of the conditions assayed.
Effects of increasing concentrations of AS-CD4-2 and
AS-CD4-4, alone or combined, were significantly higher
than that produced either by DOTAP alone or DOTAP
plus ODN-C2 and ODN-C4 (data not shown).
Effect of AS-ODNs on other lymphocyte 
surface markers
To assess the specificity of AS-ODNs, their effect on the
surface expression of other lymphocyte molecules was
studied. After 24 hours of addition of DOTAP alone (2.5, 5,
and 7.5 mM) or DOTAP plus AS-CD4-2 or AS-CD4-4
(0.75 mM), lymphocyte CD3, CD5, and CD8 surface ex-
pression was analyzed by flow cytometry. Results were ex-
pressed as MFI (Table 2) and as the percentage of inhibi-
tion of surface molecule expression with respect to that
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TABLE 2. EFFECT OF DOTAP ALONE OR COMBINED WITH AS-CD4-2 OR AS-CD4-4 
IN LYMPHOCYTE SURFACE CD3, CD5, AND CD8 EXPRESSIONa
MFI a
DOTAP
(mM) CD3 CD5 CD8
Untreated — 7.805 6 0.16 7.152 6 0.18 12.183 6 0.19
(5) (5) (5)
Dotap 2.5 7.332 6 0.18 7.003 6 0.13 13.240 6 0.15
alone (5) (5) (5)
5.5 7.637 6 0.11 7.109 6 0.17 12.932 6 0.25
(5) (5) (5)
7.5 7.487 6 0.26 6.942 6 0.12 13.064 6 0.18
(5) (5) (5)
DOTAP 1 2.5 8.325 6 0.14 7.359 6 0.08 13.719 6 0.20
AS-CD4-2 (5) (5) (5)
(0.75 mM) 5.5 8.238 6 0.24 7.433 6 0.07 14.110 6 0.31
(5) (5) (5)
7.5 8.063 6 0.44 7.314 6 0.05 13.620 6 0.30
(5) (5) (5)
DOTAP 1 2.5 7.894 6 0.22 6.950 6 0.11 12.840 6 0.38
AS-CD4-4 (5) (5) (5)
(0.75 mM) 5.5 7.755 6 0.17 6.936 6 0.06 13.400 6 0.51
(5) (5) (5)
7.5 7.725 6 0.18 6.734 6 0.08 13.821 6 0.44
(5) (5) (5)
Brackets ( ) indicate the number of samples.
aResults are expressed as mean fluorescence intensity (MFI) of positive cells after staining with FITC-conjugated
specific mAb.
determined for untreated lymphocytes. Neither AS-CD4-2
(Fig. 3A) nor AS-CD4-4 (Fig. 3B) was inhibitory in the
three cell surface molecules studied. No significant differ-
ences were observed between MFI of lymphocytes treated
with DOTAP alone and MFI of lymphocytes treated with
AS-CD4-2 or AS-CD4-4 in CD3, CD5, or CD8 expression.
Effect of AS-ODNs on surface CD4 expression
after 72 hours
Lymphocyte CD4 surface expression after treatment
with a single addition of the partially PS-modified AS-
ODNs was evaluated after 3 days (Fig. 4). The inhibitory
effect of AS-CD4-2 and AS-CD4-4 remained for at least
72 hours (p , 0.05 compared with lymphocytes treated
with DOTAP alone or treated with ODN-C2 and ODN-
C4). The effect of AS-CD4-3 also remained for 72 hours.
Unexpectedly, the nonspecific effect caused by ODN-C2
and ODN-C4 disappeared after 48 hours. Therefore, the
effect of specific AS-ODN was clearer at 2–3 days of
treatment, when the unspecific effect disappeared.
Effect of AS-CD4-2 and AS-CD4-4 on lymphocyte
CD4 mRNA expression
To test whether AS-CD4-2 and AS-CD4-4 downregu-
lated lymphocyte mRNA, CD4 mRNA expression was
quantified by RT-PCR after 24 hours and 48 hours of
AS-ODN incubation. After 24 hours, the treatment with
AS-CD4-2 and AS-CD4-4 decreased CD4 mRNA ex-
pression up to 37% and 42%, respectively (Fig. 5). At 48
hours, CD4 mRNA decreased up to 27% for AS-CD4-2
and 29% for AS-CD4-4. Therefore, the action of AS-
CD4-2 and AS-CD4-4 might be through activation of
RNAse H. In addition, CD4 mRNA expression was
quantified after ODN-C1 incubation, and the inhibitory
effect was about 5%–10% (data not shown).
Effect of AS-ODNs on proliferative response 
of T CD41 lymphocytes
The proliferative response to specific and unspecific
stimuli of T CD41 lymphocytes treated with AS-CD4-2,
AS-CD4-4, ODN-C1, and ODN-C4 is summarized in
Figure 6. Inhibition of surface CD4 expression by AS-
CD4-2 and AS-CD4-4 was confirmed before stimulus
addition. Proliferation of primed T CD41 lymphocytes
induced by OA was almost totally inhibited by treatment
with AS-CD4-2 and AS-CD4-4 (p , 0.05 with respect to
untreated or ODN-C1, ODN-C4-treated lymphocytes)
(Fig. 6A). The proliferative response to ConA of AS-
ODN-treated lymphocytes showed that AS-CD4-2 and
AS-CD4-4 partially inhibited this proliferation (p , 0.05
with respect to untreated or ODN-C1, ODN-C4-treated
lymphocytes) (Fig. 6B).
DISCUSSION
Complementary and antisense nucleic acids have been
used to regulate gene activity for 20 years. As a result,
several clinical studies focus on the use of AS-ODNs as
therapeutic drugs. PS-modified oligonucleotides are cur-
rently being evaluated in clinical trials for their ability to
CD4 EXPRESSION AND AS-ODN 223
FIG. 3. Effect of the AS-ODNs on other cell surface mole-
cules. (A) Effect of 0.75 mM AS-CD4-2 with several DOTAP
concentrations (2.5–7.5 mM) on CD3, CD5, and CD8 expression.
Results are expressed as the percentage of inhibition compared
with that of untreated lymphocytes. (B) Effect of 0.75 mM AS-
CD4-4 with several DOTAP concentrations (2.5–7.5 mM) on
CD3, CD5, and CD8 expression. Results are expressed as the
percentage of inhibition compared with untreated lymphocytes.
Each point represents the mean of five values 6 SEM.
inhibit restenosis (reviewed in Santiago and Khachigian,
2001) and various tumors (reviewed in Wang et al.,
2001). Recently, the first antisense drug, Vitravene®
(Isis Pharmaceuticals, Carlsbad, CA), was approved for
commercialization by the FDA, and several other anti-
sense drugs have shown promising activities in clinical
trials.
The CD4 membrane glycoprotein, present in Th lym-
RABANAL ET AL.224
FIG. 4. Time course of the effect of ODNs on lymphocyte CD4 surface expression for 3 days. Each point represents the mean of
six values 6 SEM.
FIG. 5. Effect of AS-CD4-2 and AS-CD4-4 on CD4 mRNA expression. HPRT mRNA was used as internal control. (Top) Rep-
resentative autoradiography of the PCR products. (Bottom) Quantitation of the bands. Each point represents the mean of three val-
ues 6 SEM.
phocytes, is essential to the immune response because it
stabilizes the physical interactions between T cells and
APCs and increases the intracellular signaling activities
triggered by antigen interaction with specific T cell re-
ceptor (Janeway, 1989; Cammarota et al., 1992). Inhibi-
tion of CD4 surface expression induces immune response
modulation. Thus, anti-CD4 mAb therapy prevents and
ameliorates rat adjuvant arthritis (Pelegrí et al., 1995,
1996). Moreover, it has been described that anti-CD4
mAb efficiently induces immune tolerance in the treat-
ment of human and other types of experimental arthritis
(Mauri et al., 1997; Isaacs et al., 1999; reviewed in
Nepom, 2002; reviewed in Keystone, 2002) and in the
prevention of transplantation rejection (Mottram et al.,
1998; Motoyama et al., 2000; reviewed in Adler and
Turka, 2002). However, mAb treatment can induce an
antiantibody response, rendering the treatment eventu-
ally ineffective (Pelegrí et al., 1996).
Surface CD4 synthesis stimulated by PMA can be re-
duced by partially PS-modified AS-ODNs directed
against cd4 mRNA (Rabanal et al., 2002). Here, we have
demonstrated that freshly isolated spleen lymphocytes
treated with the same partially PS-modified AS-ODNs
decreased CD4 surface expression. The AS-ODNs
specifically inhibited CD4 and did not affect CD3, CD5,
or CD8 molecules. The AS-ODN effect remained for at
least 72 hours. The cells used in the present study were
untreated rat spleen lymphocytes obtained early in the
morning. Rat CD4 surface expression follows a circadian
rhythm, with a daily variation of 17% (Pelegrí et al.,
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FIG. 6. Effect of AS-ODN on the proliferative response of OA-primed T CD41 lymphocytes. (A) BrdU incorporation after OA-
specific and unrelated protein (casein) stimuli. (B) BrdU incorporation after ConA stimulus. Each point represents the mean of four
values 6 SEM.
2003). The minimal number of CD4 surface molecules is
reached at the end of the active period (i.e., at the end of
the dark period in nocturnal animals), which coincides
with the maximal amount of blood Th lymphocytes.
Therefore, although the rat Th lymphocytes used in this
study were not PMA-treated, the time of the day when
they were collected and treated corresponded to the min-
imal CD4 expression, from which a certain increase in
CD4 surface expression was expected.
The administration of totally PS-modified AS-ODN
decreased CD4 surface expression, but this effect was
unspecific, as reported for PMA-treated lymphocytes
with the same AS-ODN (Rabanal et al., 2002). There-
fore, it appears that fully PS-modified AS-ODNs produce
unspecific effects on the surface CD4 expression of both
primary and PMA-treated rat lymphocytes. Taylor et al.
(1996) described an unspecific increase in tumor necrosis
factor-a (TNF-a) release after incubation of macro-
phages with fully PS-modified AS-ODN against TNF.
AS-CD4-2, with the same sequence but a distinct degree
of PS modification from AS-CD4-1, according to Pey-
man and Uhlmann (1996), showed a specific effect. This
different effect may be attributed to an increase in effi-
ciency and specificity to the hybridization to the endoge-
nous RNA when using minimal modifications. On the
other hand, CpG-containing ODNs can present im-
munostimulatory properties that are more marked in PS-
ODNs (reviewed in Krieg, 1999).
Two of the three partially PS-modified AS-ODNs ef-
fectively decreased both surface and mRNA CD4 expres-
sion. All the AS-ODNs tested were directed against the
translation start site of the rat cd4 gene, but the effective
AS-ODN had eight bases in common between the 59-
UTR and the AUG start codon. AS-ODNs may arrest
RNA translation by binding to the translational initiation
codon and the 59-UTR (Crooke, 1998, 1999). However,
their effectiveness may be conditioned to other character-
istics, such as mRNA sequences and predicted secondary
structures, which may be associated with oligonucleotide
binding. In this regard, Yun et al. (2000) examined the
inhibition of lymphocyte IL-2 secretion by AS-ODNs,
and only one of the three AS-ODNs directed against the
translation start codon displayed the desired effect.
Moreover, Boeve and De Ley (1994) studied seven AS-
ODNs against the translation initiation codon of the hu-
man interferon-g (IFN-g) mRNA, and only one caused a
significant inhibition. Therefore, the AS-ODNs directed
against the mRNA of lymphocytes were not always ef-
fective. However, other types of AS-ODNs directed
against lymphocyte mRNA inhibit some phases of im-
mune responses. Harel-Bellan et al. (1988) showed that
as AS-ODN against IL-2 inhibits the proliferation of the
Th1 clone but has no effect on Th2 clones. AS-ODNs
against IL-4 showed the opposed effect. Furthermore,
AS-ODNs effectively target lymphocyte surface CD80
and CD86 and thus prevent acute rejection allografts
(Qian et al., 2001; Liang et al., 2001). AS-ODNs directed
against cell surface molecules offer great potential for
anti-inflammatory strategies. AS-ODNs targeting inter-
cellular adhesion molecule-1 (ICAM-1) have been used
in inflammatory bowel disease and for the suppression of
allograft rejection (Stepkowski et al., 1998; Yacyshyn et
al., 1998; Van Assche and Rutgeerts, 2002). The results
of the phase I trial of ISIS 104838, a 29-methoxyethyl-
modified AS-ODN targeting TNF-a1, have recently been
published (Sewell et al., 2002). The control of the se-
creted IgM (excessive production or autoantibody) of B
lymphocytes by AS-ODNs has also been achieved in a
number of disorders, such as rheumatoid arthritis and
systemic lupus erythematosus (McCall, 1998).
Our data point to the efficacy of AS-CD4-2 and AS-
CD4-4 in downregulating mRNA expression. It appears
that AS-ODNs, by hybridizing to the target mRNA, stimu-
late RNAse H, which degrades the RNA strand of RNA-
DNA duplexes (Phillips and Gyurko, 1995). The exact
recognition elements for RNAse H are unknown. The ef-
fect of AS-CD4-2 and AS-CD4-4 remained for 72 hours,
which was the longest time lymphocytes survived without
stimulation. These data support that AS-ODNs are power-
ful immunomodulating agents against CD4. We have es-
tablished that mAb therapy against CD4 required doses ap-
plied at 48-hour intervals (Caballero et al., 1998). Thus,
although the effect of AS-ODNs on CD4 in vivo remains to
be elucidated, it may be a long-term treatment.
To assess whether the decrease in CD4 expression in-
duced by ODN was enough to block T CD41 reactivity,
specific and unspecific proliferation assays were per-
formed. T CD41 lymphocytes obtained from OA-primed
rats and treated with a single dose of the effective AS-
ODNs, AS-CD4-2 and AS-CD4-4, showed a lower reac-
tivity to polyclonal mitogen ConA. Moreover, the effec-
tive single dose of AS-CD4-2 or AS-CD4-4 almost
totally inhibited the specific reactivity of T CD41 lym-
phocytes after 4 days. These results show that although
surface and mRNA CD4 expression was not fully abol-
ished by AS-ODN at 72 hours, it was enough to block T
CD41 reactivity. In summary, we have found two AS-
ODN sequences (AS-CD4-2 and AS-CD4-4) directed
against the translation start region of cd4 that, interacting
with mRNA, reduced surface CD4 expression and almost
totally inhibited the antigen-specific immune response.
These results demonstrate the immunomodulatory power
of a single dose of AS-ODN and, therefore, its potential
as a therapeutic strategy in autoimmune diseases.
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